Bibliography
- Kimmick GG , BalducciL: Breast cancer and aging: clinical interactions.Hematol. Oncol. North Am.14, 213–234(2000).
- Moller-Jensen O , EstèveJ, MollerHet al.: Cancer in the European community and its member states.Eur. J. Cancer26, 1167–1256(1990).
- Ries LAG , KosaryCL, HankeyBFet al.: National Cancer Institute SEER cancer statistics review 973–1995 (specific data from NCHS public use tape). National Cancer Institute. Bethesda, MD, USA (1998).
- Yancik R : Cancer burden in the aged: an epidemiologic and demographic overview.Cancer80, 1273–1283(1997).
- Pike MC , KrailoMD, HendersonBEet al.: Hormonal risk factors, breast tissue age and the age-incidence of breast cancer.Nature303, 767–770(1983).
- Fentiman IS , TirelliU, MonfardiniSet al.: Cancer in the elderly: why so badly treated?Lancet335, 1020–1022(1990).
- Asano TK , McLeodRS: Non-steroidal anti-inflammatory drugs (NSAID) and aspirin for preventing colorectal adenomas and carcinomas.Cochrane Database Syst. Rev.2 (2006).
- Huls G , KoornstraJJ, KleibeukerJHet al.: Non-steroidal anti-inflammatory drugs and molecular carcinogenesis of colorectal carcinomas.Lancet362, 230–232(2003).
- Ready A , VelicerCM, McTiernanAet al.: NSAIDs use and breast cancer risk in the VITAL cohort.Breast Cancer Res. Treat. (2007) (Epub ahead of print).
- Jacobs EJ , ThunMJ, BainEBet al.: A large cohort study of long-term daily use of adult-strength aspirin and cancer incidence.J. Natl Cancer Inst99, 608–615(2007).
- García Rodríguez LA , López-RidauraR: Effects of non-steroidal anti-inflammatory drugs on cancer sites other than the colon and rectum: a meta-analysis.BMC Cancer3, 28–40(2003).
- Kopec JA , RahmanMM, BerthelotJMet al.: Descriptive epidemiology of osteoarthritis in British Columbia, Canada.J. Rheumatol.34, 386–393(2007).
- Cecchi F , MannoniA, Molino-LovaRet al.: Epidemiology of hip and knee pain in a community based sample of Italian persons aged 65 and older.Osteoarthritis Cartilage (2008) (Epub ahead of print).
- Lamont EB , DiasLE, LauderdaleDS: NSAIDs and colorectal cancer risk: do administrative data support a chemopreventive effect?J. Gen. Intern. Med.22, 1166–1171(2007).
- Williams CS , MannM, DuBoisRN: The role of cyclooxygenases in inflammation, cancer, and development.Oncogene18, 7908–7916(1999).
- Marshall SF , BernsteinL, Anton-CulverHet al.: Nonsteroidal anti-inflammatory drug use and breast cancer risk by stage and hormone receptor status. J. Natl Cancer Inst.97, 805–812(2005).
- Boland GP , ButtIS, PrasadRet al.: COX-2 expression is associated with an aggressive phenotype in ductal carcinoma in situ.Br. J. Cancer90, 423–429(2004).
- Ristimäki A , SivulaA, LundinJet al.: Prognostic significance of elevated cyclooxygenase-2 expression in breast cancer.Cancer Res.62, 632–635(1998).
- Subbaramaiah K , NortonL, GeraldWet al.: Cyclooxygenase-2 is overexpressed in HER-2/neu-positive breast cancer: evidence for involvement of AP-1 and PEA3.J. Biol. Chem.277, 18649–18657(2002).
- Swati K ulkarni, Deepa B Patil, Diaz LK et al.: COX-2 and PPARγ expression are potential markers of recurrence risk in mammary duct carcinoma in-situ. BMC Cancer8, 36 (2008).
- Tan KB , YongWP, PuttiTC: Cyclooxygenase-2 expression: a potential prognostic and predictive marker for high-grade ductal carcinoma in situ of the breast.Histopathol.44, 24–28(2004).
- Crawford YG , GauthierML, JoubelAet al.: Histologically normal human mammary epithelia with silenced p16(INK4a) overexpress COX-2, promoting a premalignant program.Cancer Cell5, 263–273(2004).
- Brodie AM , LuQ, LongBJet al.: Aromatase and COX-2 expression in human breast cancers.J. Steroid Biochem. Mol. Biol.79, 41–47(2001).
- Harris RE , AlshafieGA, SeibertK: Chemoprevention of breast cancer in rats by celecoxib, a cyclooxygenase 2 inhibitor.Cancer Res.60, 2101–2103(2000).
- Kubatka P , AhlersI, AhlersováEet al.: Chemoprevention of mammary carcinogenesis in female rats by rofecoxib.Cancer Lett.202, 131–136(2003).
- Thun MJ , HenleySJ, PatronoC: Nonsteroidal anti-inflammatory drugs as anticancer agents: mechanistic, pharmacologic and clinical issues.J. Natl Cancer Inst94(4), 252–256(2002).
- Brodie AM , LuQ, LongBJet al.: Aromatase and COX-2 expression in human breast cancers.J. Steroid Biochem. Mol. Biol.79, 41–47(2001).
- Brueggemeier RW , QuinnAL, ParrettMLet al.: Correlation of aromatase and cyclooxygenase gene expression in human breast cancer specimens. Cancer Lett.140, 27–35(1999).
- Elvin JA , YanC, MatzukMM: Growth differentiation factor-9 stimulates progesterone synthesis in granulosa cells via a prostaglandin E2/EP2 receptor pathway.Proc. Natl Acad. Sci.97, 10288–10293(2000).
- Subbaramaiah K , HoweLRet al.: Port ERHER-2/neu status is a determinant of mammary aromatase activity in vivo: evidence for a cyclooxygenase-2-dependent mechanism.Cancer Res.66, 5504–5511(2006).
- Müller-Decker K , BergerI, AckermannKet al.: Cystic duct dilatations and proliferative epithelial lesions in mouse mammary glands upon keratin 5 promoter-driven overexpression of cyclooxygenase-2. Am. J. Path.166, 575–584(2005).
- Friedman GD , UryHK: Initial screening for carcinogenicity of commonly used drugs.J. Natl Cancer Inst.65, 723–733(1980).
- Paganini-Hill A , ChaoA, RossRKet al.: Aspirin use and chronic diseases: a cohort study of the elderly.Br. Med. J.299, 1247–1250(1989).
- Thun MJ , NamboodiriMM, CalleEEet al.: Aspirin use and risk of fatal cancer.Cancer Res.53, 1322–1327(1993).
- Schreinemachers DM , EversonRB: Aspirin use and lung, colon, and breast cancer incidence in a prospective study.Epidemiology5, 138–146(1994).
- Egan KM , StampferMJ, GiovannucciEet al.: Prospective study of regular aspirin use and the risk of breast cancer. J. Natl Cancer Inst.88, 988–993(1996).
- Harris RE , KasbariS, FarrarWBet al.: Prospective study of nonsteroidal anti-inflammatory drugs and breast cancer.Oncol. Rep.6, 71–73(1999).
- Johnson TW , AndersonKE, LazovichDet al.: Association of aspirin and nonsteroidal anti-inflammatory drug use with breast cancer. Cancer Epidemiol. Biomarkers Prev.11, 1586–1591(2002).
- S⊘rensen HT , FriisS, N⊘rgårdBet al.: Risk of cancer in a large cohort of nonaspirin NSAID users: a population-based study.Br. J. Cancer88, 1687–1692(2003).
- Harris RE , ChlebowskiRT, JacksonRDet al.: Breast cancer and nonsteroidal anti-inflammatory drugs: prospective results from the women‘s health initiative. Cancer Res.63, 6096–6101(2003).
- Harris HE , NamboodiriK, StellmanSDet al.: Breast cancer and NSAID use: heterogeneity of effect in a case–control study. Prev. Med.24, 119–120(1995).
- Rosenberg L : Nonsteroidal anti-inflammatory drugs and cancer.Prev. Med.24, 107–109(1995).
- Harris HE , NamboodiriK, FarrarWB: Nonsteroidal anti-inflammatory drugs and breast cancer.Epidemiology7, 203–205(1996).
- Neugut AI , RosenbergDJ, AhsanHet al.: Association between coronary heart disease and cancers of the breast, prostate and colon.Cancer Epidemiol. Biomarkers Prev.7, 869–873(1998).
- Coogan PF , RaoSR, RosenbergLet al.: The relationship of nonsteroidal anti-inflammatory drugs use to the risk of breast cancer.Prev. Med.29, 72–76(1999).
- Langman MJ , ChengKK, GilmanEAet al.: Effect of anti-inflammatory drugs on overall risk of common cancer: case–control study in general practice research database.Br. Med. J.320, 1642–1646(2000).
- Sharp CR , ColletJP, McNuttMet al.: Nested case–control study of the effects of nonsteroidal anti-inflammatory drugs on breast cancer risk and stage.Br. J. Cancer83, 112–120(2000).
- Cotterchio M , KreigerN, SteingartAet al.: Nonsteroidal anti-inflammatory drug use and breast cancer.Cancer Epidemiol. Biomarkers Prev.1213–1217(2001).
- Meier CR , SchmitzS, JickH: Association between acetaminophen or nonsteroidal anti-inflammatory drugs and risk of developing ovarian, breast, or colon cancer.Pharmacotherapy22, 303–309(2002).
- Moorman PG , GrubberJM, MillikanRCet al.: Association between non-steroidal anti-inflammatory drugs (NSAIDs) and invasive breast cancer and carcinoma in situ of the breast. Cancer Causes Control14, 915–922(2003).
- García Rodríguez LA , González-PérezA: Risk of breast cancer among users of aspirin and other anti-inflammatory drugs.Br. J. Cancer91, 525–529(2004).
- Terry MB , GammonMD, ZhangFFet al.: Association of frequency and duration of aspirin use and hormone receptor status with breast cancer risk.JAMA291, 2433–2440(2004).
- Zhang YQ , CooganPF, PalmerJRet al.: Use of nonsteroidal antiinflammatory drugs and risk of breast cancer: the case–control surveillance study revisited.Am. J. Epidemiol.162, 165–170(2005).
- Baron JA , ColeBF, SandlerRSet al.: A randomized trial of aspirin to prevent colorectal adenomas.N. Eng. J. Med.348, 891–899(2003).
- Patrono C , CollerB, FitzGeraldGAet al.: Platelet-active drugs: the relationships among dose, effectiveness, and side effects: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy.Chest126, 234S–264S (2004).
- Kirsh VA , KreigerN, CotterchioMet al.: Nonsteroidal antiinflammatory drug use and breast cancer risk: subgroup findings.Am. J. Epidemiol.166, 709–716(2007).
- Daidone MG , CoradiniD, MartelliGet al.: Primary breast cancer in elderly women: biological profile and relation with clinical outcome.Crit. Rev. Oncol. Hematol.45, 313–325(2003).
- Fisher CJ , EganMK, SmithPet al.: Histopathology of breast cancer in relation to age.Br. J. Cancer75, 593–596(1997).
- Gennari R , CurglianoG, RotmenszNet al.: Breast carcinoma in elderly women.Cancer101, 1302–1310(2004).
- Singh G , TriadafilopoulosG: Appropriate choice of proton pump inhibitor therapy in the prevention and management of NSAID-related gastrointestinal damage.Int. J. Clin. Pract.59, 1210–1217(2005).
- Savage R : Cyclo-oxygenase-2 inhibitors: when should they be used in the elderly.Drugs Aging22, 185–200(2005).